Senior Team Members
Jon Burrows, PhD
Dr. Burrows is a founding member and Managing Director of Oncology Partners.
He was originally trained as an industrial chemist at the University of Leeds and received a Master’s Degree in physical chemistry and a Ph.D. in cell and molecular biology from the University of Nevada - Reno. As a postdoctoral fellow at Washington University School of Medicine in St. Louis, Dr. Burrows was awarded the inaugural Alpha One Foundation Fellowship.
Dr. Burrows drug development career has been built on increasing levels of responsibility in scientific leadership, business development and executive management at major biomedical entities, including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana and Roche.
Prior to co-founding Oncology Partners, Dr. Burrows was President and CEO of OncoPlex Diagnostics. During his tenure as CEO, Dr. Burrows successfully rebranded the company and used his accumulated experience and network in oncology drug development, clinical trials and molecular diagnostics to successfully transform what was initially an early stage research and tools company into a clinical diagnostics company with marketed products and significant sales traction. As a result of Dr. Burrows’ efforts to refocus the company, OncoPlex successfully completed a high dollar value acquisition with NantOmics in 2015.
Jedd Levine, MD, MBA
Dr. Levine is a founding member and Executive Vice President, Clinical Affairs of Oncology Partners.
Dr. Levine is an oncologist and practiced clinical oncology for 30 years. Prior to founding Oncology Partners, Dr. Levine was Managing Partner of Connecticut Oncology and Hematology, LLC. In addition to his clinical background, Dr. Levine also served as Chief Medical Officer of Egenix, a development stage oncology company based on technology licensed from Harvard Medical School, and as Chief Medical Officer of OncoPlex Diagnostics, a molecular diagnostics company focused on personalized medicine for cancer patients. He currently serves as Chief Medical Officer of Bantam Pharmaceutical, which is developing novel therapeutics against cancer.
Dr. Levine received his MD from Harvard Medical School and his MBA from Columbia Business School. He was a Research and Clinical Fellow and faculty member in the Division of Oncology, Stanford University and also served as a member of the faculty of Yale Medical School.
Mr. Lucchese is a founding member and Managing Director of Oncology Partners.
Mr. Lucchese has over 25 years of experience investing in and advising early stage companies. Prior to founding Oncology Partners, Mr. Lucchese was a founder and Managing Partner of Foundation Ventures, an investment banking firm servicing early stage life sciences companies.
Mr. Lucchese was also a Managing Director at BlueStone Capital Partners where he ran the Private Placement desk. Prior to BlueStone, Mr. Lucchese was Portfolio Manager and Chief Financial Officer of the MicroCap Fund, a NASDAQ-listed private equity fund that invested in early stage companies in the healthcare and information technology sectors.
He has served as a board member and a founding partner in numerous companies during the course of his career. He began his career as a member of Chase Manhattan Bank’s Merchant Banking Group where he was part of a team that financed highly leveraged transactions and managed the bank’s private equity portfolio.